ClinicalTrials.gg
CompletedNCT01911741Updated Jul 30, 2013

A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

A Phase 1 interventional study of MDV3100 in Healthy Subjects, Castration Resistant Prostate Cancer (CRPC) and Relative Bioavailability, sponsored by Astellas Pharma Europe B.V.. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-30.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
62nd of 125
55 · median 52
Started
2012
with 4 others
Phase 1
22 of 125
2 open now
Registered
16th of 125
by date
Lead sponsor
6 of 125
Astellas Pharma Europe B.V.

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 62nd largest by enrollment, is one of 5 that started in 2012, is one of 22 in phase 1, and was the 16th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A study to evaluate the bioavailability (BA) of a single oral dose of MDV3100 (enzalutamide) formulated as a solid spray dried tablet compared to oral liquid-filled capsules, and the safety and tolerability of oral formulations.

Subjects are admitted to the clinic from days 1 to 5, followed by outpatient assessments up to Day 50. They return to the clinic for an end of study visit (ESV) 7-10 days after the last pharmacokinetic (PK) sampling or after early withdrawal.

03

Conditions studied

  • Healthy Subjects
  • Castration Resistant Prostate Cancer (CRPC)
  • Relative Bioavailability
  • MDV3100

Browse trials for

Keywords

  • Phase I
  • Enzalutamide
  • Relative bioavailability of MDV3100
  • Immediate release oral formulation
  • Xtandi
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has a (BMI) range of 18.5 - 29.9 kg/m2, inclusive. The subject weighs at least 50 kg (screening).
  • Male subject and his female spouse/partner who is of must be using highly effective consisting of two forms of birth control (one of which must be a barrier method) starting at screening and continue throughout the study period and for 3 months after final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the study period and for at least 3 months after final study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to enzalutamide, or any components of the formulation used.
  • Confirmed CYP2C8 poor metabolizer status based on genotyping analysis.
  • Any history of seizure including a febrile seizure in childhood, loss of consciousness, , or any condition that may pre-dispose to seizure.
  • The subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to first clinic check in.
  • Use of grapefruit or marmalade in the week prior to admission to the Clinical Unit, as reported by the subject.
  • Any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission on Day -1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Treatment A

    Single dose of 4 liquid-filled capsules of MDV3100 reference formulation

    Drug: MDV3100

  • Experimental
    Treatment B

    Single dose of 2 tablets of MDV3100 formulation tablet B

    Drug: MDV3100

  • Experimental
    Treatment C

    Single dose of 2 tablets of MDV3100 formulation tablet C

    Drug: MDV3100

Interventions

  • Oral

    Also known as: enzalutamide, Xtandi

06

What researchers measure

Primary outcomes

  1. Relative BA of capsule and tablet formulations of enzalutamide following a single dose of enzalutamide under fasted conditions

    AUC0-t (Area Under Curve from time zero to last quantifiable sample), AUC0-inf (AUC extrapolated to infinity), Cmax (Maximum concentration)

    Time frame: Day 1 through Day 50 (26 times)

Secondary outcomes

  1. Relative BA of capsule and tablet formulations of enzalutamide following a single dose of enzalutamide under fasted conditions

    AUC0-72h (AUC from time zero to 72h post dose), AUC0-t, AUC0-inf, %AUC (Percentage of AUC), Cmax, tmax (Time to attain Cmax), λz (Terminal elimination rate constant), t1/2 (Terminal elimination half life), (MPR) metabolites to parent ratio, MPR(molecular weight corrected \[MWC\]), %AUC, CL/F (apparent oral clearance), Vz/F (apparent volume of distribution)

    Time frame: Day 1 through Day 50 (26 times)

  2. Safety and tolerability of oral formulations of enzalutamide

    adverse events, physical examination, vital signs, clinical laboratory tests, 12-lead Electrocardiogram (ECG)

    Time frame: Screening through ESV (7-10 days after the last pharmacokinetic (PK) sampling or after early withdrawal)

07

Study locations

1 site
  • Parexel International GmbH
    Berlin, 14050, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2013
First posted
Jul 30, 2013
Start
Nov 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Last update
Jul 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01911741
Collaborators
Medivation, Inc.
Responsible party
Sponsor
First posted
Jul 30, 2013
Start date
Nov 2012
Primary completion
Mar 2013
Completion
Mar 2013
Last update
Jul 30, 2013

Study contacts

Study Manager
study chair · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion